Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | Phase
Phase 1
|
Date Added 2015-11-17 |
Location |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
Tags
MSS/ MMRp
|
| NCT ID PG545 (pixatimod) in combination with nivolumab |
TitlePG545 (pixatimod) in combination with nivolumab | Phase
Phase 1
|
Date Added 2019-04-26 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06923761 |
TitleEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1) | Phase
Phase 1, Phase 2
|
Date Added 2025-04-11 |
Location
Australia
France Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06856837 |
Title– IKF/AIO-QUINTIS – Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | Phase
Phase 2
|
Date Added 2025-03-04 |
Location
Austria
Germany |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06850103 |
TitleSCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases | Phase
Phase 2
|
Date Added 2025-02-27 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06841159 |
TitlePersonalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-03-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06835179 |
TitleSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | Phase
Phase 2
|
Date Added 2025-02-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06801665 |
TitleFMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis | Phase
Phase 2
|
Date Added 2025-01-30 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06794086 |
TitleSBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases | Phase
Phase 3
|
Date Added 2025-01-27 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06792695 |
TitleA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-01-27 |
Location
Arizona, United States
California, United States District of Columbia, United States Illinois, United States Maryland, United States Massachusetts, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada China France Germany Italy Netherlands South Korea Spain Taiwan United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
